Praxis Precision Medicines
Logotype for Praxis Precision Medicines Inc

Praxis Precision Medicines (PRAX) investor relations material

Praxis Precision Medicines UBS Global Biopharma Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Praxis Precision Medicines Inc
UBS Global Biopharma Conference 2026 summary16 Nov, 2026

Portfolio and growth strategy

  • Two NDAs and 21 programs; ulixacaltamide, referred to as Ulixa, is the portfolio’s near-term focus, with essential tremor affecting 9 million Americans.

  • Three ulixacaltamide extension studies are starting soon in restless legs syndrome, Parkinson’s tremor and autism spectrum disorder; management described restless legs as clinically higher-risk but attractive on risk-reward.

  • The potential essential tremor market was characterized as $36 billion, versus a prior $10 billion estimate; the launch plan emphasizes controlled patient experience and broad prescribing-base coverage.

Ulixacaltamide regulatory and clinical outlook

  • Ahead of the January 29 PDUFA, management said the late-cycle FDA meeting felt more like a label discussion and expressed high confidence in approval; further work includes final label and possible PMC/PMR agreements.

  • Management described the expected label as broad: adult essential tremor studies showed all subgroups nominally superior to placebo, with no expected renal, hepatic or CYP3A4-related restrictions, contraindications, black box warning or REMS.

  • Management said scheduling is likely, while noting possible Schedule IV, Schedule V or no scheduling; it expects no meaningful launch difference, with neurologists as the target prescribers.

  • Long-term follow-up showed sustained improvement; the goal is ~200 patients with two years of follow-up, with more data expected soon and potentially in early January. Ulixacaltamide is intended as chronic treatment.

  • Initial dizziness and brain fog can be challenging for some patients but reportedly improve with continued treatment; launch strategy prioritizes managing that experience while generating demand.

Commercial readiness

  • Praxis Horizon is operational and has completed end-to-end test scripts, integrating prescribing through dispensing and reimbursement workflows.

  • The system is designed to support prescribing in physicians’ EMRs, automate prior-authorization data transfer and route prescriptions through a Praxis pharmacy, reducing paperwork and prescription attrition.

  • Management plans significant launch resources and coverage of the full prescribing base, aiming to balance demand generation with controlled patient experience.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Praxis Precision Medicines earnings date

Logotype for Praxis Precision Medicines Inc
Q4 202623 Feb, 2027
Praxis Precision Medicines
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Praxis Precision Medicines earnings date

Logotype for Praxis Precision Medicines Inc
Q4 202623 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. The company leverages genetic insights and a precision medicine approach to develop treatments for conditions such as epilepsy, movement disorders, and psychiatric conditions. Praxis is dedicated to addressing unmet medical needs through targeted therapies aimed at neurological circuits and pathways that are implicated in various CNS diseases. Its pipeline includes a range of investigational treatments designed to offer new therapeutic options for patients with these complex conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.